[go: up one dir, main page]

WO2004014293A3 - Combination of anti-muscarinic agents and non-glucocorticoid steroids - Google Patents

Combination of anti-muscarinic agents and non-glucocorticoid steroids Download PDF

Info

Publication number
WO2004014293A3
WO2004014293A3 PCT/US2003/018967 US0318967W WO2004014293A3 WO 2004014293 A3 WO2004014293 A3 WO 2004014293A3 US 0318967 W US0318967 W US 0318967W WO 2004014293 A3 WO2004014293 A3 WO 2004014293A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
muscarinic agents
glucocorticoid steroids
salts
glucocorticoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/018967
Other languages
French (fr)
Other versions
WO2004014293A2 (en
Inventor
Jonathan W Nyce
Cynthia B Robinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epigenesis Pharmaceuticals Inc
Original Assignee
Epigenesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc filed Critical Epigenesis Pharmaceuticals Inc
Priority to AU2003276837A priority Critical patent/AU2003276837B2/en
Priority to MXPA04012410A priority patent/MXPA04012410A/en
Priority to BR0311747-2A priority patent/BR0311747A/en
Priority to JP2004527571A priority patent/JP2006504666A/en
Priority to CA002487399A priority patent/CA2487399A1/en
Priority to EP03784741A priority patent/EP1511500A4/en
Publication of WO2004014293A2 publication Critical patent/WO2004014293A2/en
Publication of WO2004014293A3 publication Critical patent/WO2004014293A3/en
Priority to IL16509304A priority patent/IL165093A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A pharmaceutical or veterinary composition comprises a non-corticosteroids, and/or salts thereof, and an antimuscarinic (anti-cholinergic) agent, and/or pharmaceutically or veterinarilly acceptable salts thereof. The composition is provided in carious formulations and in the form of a kit. The products of this patent are useful in the prophylaxis and treatment of various respiratory, lung and malignant diseases.
PCT/US2003/018967 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids Ceased WO2004014293A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2003276837A AU2003276837B2 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids
MXPA04012410A MXPA04012410A (en) 2002-06-12 2003-06-12 Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s).
BR0311747-2A BR0311747A (en) 2002-06-12 2003-06-12 Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease
JP2004527571A JP2006504666A (en) 2002-06-12 2003-06-12 Compositions, formulations and kits for treating respiratory and pulmonary diseases with dehydroepiandrosterone steroids and antimuscarinic agents
CA002487399A CA2487399A1 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids
EP03784741A EP1511500A4 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids
IL16509304A IL165093A0 (en) 2002-06-12 2004-11-08 Composition, formulations and kit for treatment ofrespiatory and lung disease with dehydroepiandros terone(s)steroid and an anti-muscarinic agent(s)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38817002P 2002-06-12 2002-06-12
US60/388,170 2002-06-12

Publications (2)

Publication Number Publication Date
WO2004014293A2 WO2004014293A2 (en) 2004-02-19
WO2004014293A3 true WO2004014293A3 (en) 2004-09-23

Family

ID=31715648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018967 Ceased WO2004014293A2 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids

Country Status (10)

Country Link
EP (1) EP1511500A4 (en)
JP (1) JP2006504666A (en)
KR (1) KR20060011783A (en)
CN (2) CN1674918A (en)
AU (1) AU2003276837B2 (en)
BR (1) BR0311747A (en)
CA (1) CA2487399A1 (en)
IL (1) IL165093A0 (en)
MX (1) MXPA04012410A (en)
WO (1) WO2004014293A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ES2257152B1 (en) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS.
SI1765404T1 (en) * 2004-05-31 2009-04-30 Almirall Lab Combinations comprising antimuscarinic agents and beta-adrenergic agonists
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
MX2008001506A (en) * 2005-08-06 2008-04-07 Boehringer Ingelheim Int Use of tiotropium salts in the treatment of severe persistant asthma.
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
WO2008097525A2 (en) * 2007-02-05 2008-08-14 Potentia Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
ES2712988T5 (en) 2013-03-15 2022-10-21 Pearl Therapeutics Inc Methods and systems for conditioning particulate crystalline materials
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
US20210331982A1 (en) * 2018-09-07 2021-10-28 Allied Mineral Products, Llc Dry refractory compositions with reduced levels of respirable crystalline silica

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429187A1 (en) * 1989-10-26 1991-05-29 ELAN CORPORATION, Plc Enhanced bioavailability adsorbates
US6087351A (en) * 1995-02-24 2000-07-11 East Carolina University Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone
US6150348A (en) * 1993-03-09 2000-11-21 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
RO117414B1 (en) * 1992-12-09 2002-03-29 Jager Paul D Waterbury Pharmaceutical composition of gas dispersoid in solution
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
PT1292281E (en) * 2000-10-12 2004-11-30 Boehringer Ingelheim Pharma NEW POSSESSION FOR INHALATION CONTAINING TIOTROPIO
WO2002085297A2 (en) * 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
WO2002085296A2 (en) * 2001-04-24 2002-10-31 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429187A1 (en) * 1989-10-26 1991-05-29 ELAN CORPORATION, Plc Enhanced bioavailability adsorbates
US6150348A (en) * 1993-03-09 2000-11-21 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US6087351A (en) * 1995-02-24 2000-07-11 East Carolina University Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems

Also Published As

Publication number Publication date
AU2003276837B2 (en) 2006-07-20
BR0311747A (en) 2005-06-07
AU2003276837A1 (en) 2004-02-25
WO2004014293A2 (en) 2004-02-19
CN101700247A (en) 2010-05-05
CA2487399A1 (en) 2004-02-19
IL165093A0 (en) 2005-12-18
KR20060011783A (en) 2006-02-03
EP1511500A2 (en) 2005-03-09
CN1674918A (en) 2005-09-28
MXPA04012410A (en) 2005-10-19
EP1511500A4 (en) 2009-04-29
JP2006504666A (en) 2006-02-09
AU2003276837A2 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
WO2002085296A3 (en) Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
WO2004014293A3 (en) Combination of anti-muscarinic agents and non-glucocorticoid steroids
WO2004037807A3 (en) Medicinal arylethanolamine compounds
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
WO2005120461A3 (en) Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
EP1830191A3 (en) Pharmaceutical preparations containing thiazolidinediones for the treatment of endocrine autoimmune diseases
CA2436540A1 (en) Pharmaceutical compositions based on anticholinergics and corticosteroids
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2002085309A9 (en) Composition, formulations & kits for treatment of respiratory & lung disease with anti-sense oligonucleotides & a bronchodilating agent
WO2005011614A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
AU2003260241A1 (en) Buguzhi agent and composition and methods of preparing and administering the same
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
AU2001258395A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
IL167250A (en) Chirale oxazole-arylpropionic acid derivatives, compositions comprising thereof and their use in the preparation of medicaments for the treatment of ppar alpha/ ppar gamma agonists-modulated diseases
WO2005011608A3 (en) PHARMACEUTICAL COMPOSITION COMPRISING A NON-GLUCOCORTICOID STEROID AND A cAMP INHIBITOR
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
AU2003290015A1 (en) Mastitis treatment
SE9902935D0 (en) Pharmaceutical compositions
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
SE9902937D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 165093

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3481/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003276837

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003784741

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2487399

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004527571

Country of ref document: JP

Ref document number: PA/a/2004/012410

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047020226

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 20038193000

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003784741

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047020226

Country of ref document: KR